STUDY OF THE PHOTOSTABILITY OF Α-LIPOIC ACID AND MOXIFLOXACIN ENCAPSULATED IN HALLOYSITE
DOI:
https://doi.org/10.35546/kntu2078-4481.2023.2.14Keywords:
α-lipoic acid, moxifloxacin, halloysite nanotubes, encapsulation, high performance liquid chromatography, photostabilityAbstract
In this work, the widely used active pharmaceutical ingredients (AFI) α-lipoic acid (ALA) and moxifloxacin (MF) were investigated. Possessing a wide range of therapeutic properties and antioxidant capacity, these ingredients lose their therapeutic potential during storage under the influence of daylight due to the formation of photodegradation products and a decrease in the effective therapeutic concentration. One of the ways to increase the shelf life of biodegradable ingredients while preserving their therapeutic activity is encapsulation in a nanocarrier, among which the non-toxic biologically safe natural mineral – halloysite is popular. In the work, the technique of vacuum encapsulation in halloysite nanotubes (HNTs) of active pharmaceutical ingredients – α-lipoic acid and moxifloxacin was developed. Nanocomposite materials based on halloysite nanotubes and pharmaceutical ingredients – HNTs ALA and HNTs-MF were obtained. Loading control was carried out by TEM microscopy. The photostability of the obtained nanocomposite materials was tested at daytime temperatures during the day. The photostability of individual components in the native state was investigated in the composition of the aqueous dispersion of HNTs and AFI. Control of changes in the concentration of organic substances was carried out using high-performance liquid chromatography. It was established that the encapsulated active pharmaceutical ingredients in the composition of halloysite nanotubes are more stable than in their native state. Photodegradation of pharmaceutical ingredients under the influence of sunlight quanta occurs due to the destruction of bonds in the molecules of organic compounds with the formation of degradation products. Testing has shown that encapsulation in halloysite nanotubes can protect α-lipoic acid (ALA) and moxifloxacin at 98.5% and 99.9%, respectively. In the native state after a day of testing, the residual content of α-lipoic acid and moxifloxacin is 82.0% and 89.0%, respectively.
References
Cavallaro, G., Chiappisi, L., Pasbakhsh, P., Gradzielski, M., Lazzara, G. A. Structural comparison of halloysite nanotubes of different origin by small-angle neutron scattering (SANS) and electric birefringence. Appl. Clay Sci. 160. 2018. p. 71–80.
Ojo, O.F., Farinmade, A., Trout, J., Omarova, M., He, J., John, V., Blake, D.A., Lvov, Y.M., Zhang, D., Nguyen, D., Bose, A. Stoppers and skins on clay nanotubes help stabilize oil-in-water emulsions and modulate the release of encapsulated surfactants. ACS Appl. Nano Mater. 2, 2019. p. 3490–3500.
Price, R.R., Gaber, B.P., Lvov, Y. In vitro release characteristics of tetracyline HCl, khellin and nicotinamide adenine dinucloetide from halloysite; a cylindrical mineral. J Microencapsul. 18, 2001. p. 713.
Fakhrullina, G.I., Akhatova, F.S., Lvov, Y.M., Fakhrullin, R.F. Toxicity of halloysite clay nanotubes in vivo: a Caenorhabditis elegans study. Environ. Sci. Nano 2, 2018. p. 54–59.
Price, R., Gaber, B., Lvov, Y.M. In-vitro release characteristics of tetracycline, khellin and nicotinamide adenine dinucleotide from halloysite a cylindrical mineral for delivery of biologically active agents. J. Microencapsul. 18, 2001. p. 713–723.
Veerabadran, N., Price, R., Lvov, Y.M. Clay nanotubules for drug encapsulation and sustained release. Nano 2, 2007. p. 215–222.
Ruktanonchai, U.; Bejrapha, P.; Sakulkhu, U.; Opanasopit, P.; Bunyapraphatsara, N.; Junyaprasert, V.; Puttipipatkhachorn, S. Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid. AAPS Pharm. Sci. Tech., 2009, 10, p. 227–234.
Dima, S., Dima, C., & Iordăchescu, G. Encapsulation of functional lipophilic food and drug biocomponents. Food Engineering Reviews, 7. 2014. p. 417–438.
Eliopulos GM. Activity of newer fluoroquinolones in vitro against gram-positive bacteria. Drugs. 1999. p. 23–28.
Sharma SK, George N, Kdhiravan T, Saha PK, Mishra HK, Hanif M. Prevalence of extensively drug resistant tuberculosis among patients with multidrug-resistant tuberculosis: a retrospective hospital-based study. Indian J Med Res. 2009; p. 392–395.
Hidalgo ME, Pessoa C, Fernandez E, Cardenas AM. Comparative determination 232 of photodegradation kinetics of quinolones. J Photochem Photobiol A Chem. 1993; p. 135–138.
Burhenne J, Ludwig M, Nikoloudis P, Spiteller M. Photolytic degradation of fluoroquinolone carboylic acid in aqueous solution. Part I: primary photoproducts and halflives. Environ Sci Pollut Res. 1997. p. 10–15.
Burhenne J, Ludwig M, Spiteller M. Photolytic degradation of fluoroquinolone carboylic acid in aqueous solution. Part II: isolation and structural elucidation of polar photometabolities. Environ Sci Pollut Res. 1997. p. 61–67.
Levis S. & Deasy P. Use of coated microtubular halloysite for the sustained release of diltiazem hydrochloride and propranolol hydrochloride. International Journal of Pharmaceutics, 253. 2003. p. 145–157.
Ward C.J., Song S. & Davis E.W. Controlled release of tetracycline–HCl from halloysite–polymer composite films. Journal of Nanoscience and Nanotechnology, 10.2010. p. 6641–6649.
Price R., Gaber B. & Lvov Y. In-vitro release characteristics of tetracycline HCl, khellin and nicotinamide adenine dineucleotide from halloysite; a cylindrical mineral. Journal of Microencapsulation, 18. 2001. p. 713–722.
Tan D., Yuan P., Annabi-Bergaya F., Liu D.,Wang L., Liu H. & He H. Loading and in vitro release of ibuprofen in tubular halloysite. Applied Clay Science, 96. 2014. p. 50–55.
Wang, Q., Zhang, J., Zheng, Y., Wang, A. Alkali activation of halloysite for adsorption and release of ofloxacin. Appl. Surf. Sci. 287. 2013. p. 54–61.
ICH Q1B. Photostability testing of new drug substances and products. Fed. Regist. 62. 1997. p. 27115–27122.
